Method for screening compounds against flaviviruses by using persistent virus-infected cell system

ABSTRACT

This invention provides a method for screening compounds against  Flavivirus.  More specifically, this invention provides a method for screening compounds against  Flaviviruses  by using a persistent virus-infected cell system, including (a) establishment of persistent virus-infected cell lines, (b) preparation of monoclonal antibody by using said persistent virus-infected cell lines, (c) incubation of tested compounds with said persistent virus-infected cell lines, (d) determination of the inhibition effect of tested compounds or vaccines on  Flavivirus  by sandwich ELISA using said monoclonal antibody.

FIELD OF THE INVENTION

This invention relates to methods for screening compounds against virusinfection, and more particularly, to a method for screening compoundsagainst Flaviviruses by using a persistent virus-infected cell system.

BACKGROUND OF THE INVENTION

Flaviviridae family comprises three genuses of Flavivirus, Pestivirus,and Hepacivirus. Genus Flavivirus genomes consist of a linear,single-stranded, positive sense RNA having a total genome range of 10 to11 kilobase pairs, which forms a structure of 5′-stucturalgenes-nonstructural genes-3′. The 3′ terminus of Flavivirus genomes isnot polyadenylated, and the 5′ end has a methylated nucleotide cap(allowing for translation) or a genome-linked protein. Virus structuralgenes on 5′-end occupy one-fourth of the whole genome, which comprisesC, prM, and E genes, and non-structural genes occupy the remaining partsof the genome. The virions appear roughly as spheres, 40-65 nm indiameter comprising three structural proteins: truncated envelopeprotein (E protein), membrane protein (M protein), and capsid protein (Cprotein). The number of viral non-structural proteins existing inFlavivirus-infected cells is not quite sure. However there are at leastthree non-structural proteins identified in Flavivirus-infected cellsand those proteins are highly related to viral RNA replication, whereinat least one protein has a proteinase function. Truncated envelopeprotein (E protein) is a viral agglutinin that will allow infected cellsto adhere hemoglobin. The 5′-UTR (un-translated region) is a highlyconserved region in viral genome and an important part in the initiationor control of protein translation (Thurner C., et al., J Gen Virol. 2004May; 85(Pt 5): 1113-24; Henchal E. A. and Putnak J. R. Clin MicrobiolRev. 1990 October; 3(4): 376-396; Chambers T. J. et al., Annu RevMicrobiol. 1990; 44:649-88.)

Genus Flavivirus comprises at least 65 species being either directpathogens for humans or zoonosis. Except for the hepatitis C virus,which is spread by body fluid contact, the media for other viruses arearthropods such as mosquitoes or ticks. There are three clinicalsyndromes observed for Flavivirus infection including: central neurondisease caused by Flavivirus such as St. Louis encephalitis, murrayvalley encephalitis, Japanese encephalitis, and the like; systematicdisorder caused by yellow fever virus infecting organs; and seriousmuscle disorders (such as acute flaccid paralysis (AFP), peripheraldemyelinating process (Guillain-Barré Syndrome (GBS), anterior myelitisand the like), and hemorrhagic fever caused by West Nile virus, denguefever virus, and the like). According to estimation from the WorldHealth Organization (WHO), just for the dengue fever virus, about 2million infections result every year globally. Over two thousand casesincluding 77 deaths have been reported for the West Nile virus infectionfrom January to November of 2004 according to statistical data publishedby the CDC (USA) dated on Nov. 8, 2004. Flavivirus infection has becomea major issue on worldwide epidemiology.

The infection of Flavivirus needs to be confirmed by virus isolation andserological identification; wherein yellow fever virus, dengue virus,and some encephalitis cases caused by ticks can be isolated from a bloodsample. However, the serological identification of virus is not usefulfor therapy due to the low crossover antibody protection. Further, avaccine for Japanese encephalitis has been widely used for years;however, because said vaccine is a live attenuated virus vaccine,there's a lime limitation for titer maintenance. In the past, people whohad received vaccination used to obtain a natural boost due tofrequently being bilten by mosquitoes. The chance to get a natural boostis lower today due to improved living conditions. Therefore, there arestill some Japanese encephalitis infected cases reported from vaccinatedadults. Currently, antiviral drugs are available for the treatment ofHIV, herpes virus (pathogens for various diseases such as Herpeslabialis or encephalitis), and hepatitis B or C viruses (both can resultin liver cancer). There is no available or anticipated drug for theclinical treatment of Flavivirus infection, and syndrome supportivetherapy has been applied in most cases. Therefore, it is urgently neededto have a simple and rapid method for screening natural or syntheticcompounds that might be useful in preventing the Flavivirus infection.

The currently used screening method for anti-virus drugs comprises:infecting cells with virus, culturing the infected cells in a culturemedium, adding possible compounds to the culture medium, and furtherexamining the compounds to see which can decrease viral numbers. Theabove method is not economically efficient in that the laboratory staffneeds to frequently repeat the step of infecting cells with virus. Inaddition, compounds selected by the above screening method are notguaranteed to inhibit intercellular viral protein expression. There arestill some doubts as to whether or not the selected compounds can entercells and the expressed cytoxicity on cells.

SUMMARY OF THE INVENTION

To solve the obstacles existing in current screening methods for drugsor lead compounds, this invention provides a screening method forcompounds against Flavivirus infection, comprising the steps of: (a)establishment of persistent virus-infected cell lines, (b) preparationof monoclonal antibody by using said persistent virus-infected celllines, (c) incubation of tested compounds with said persistentvirus-infected cell lines, and (d) determination of the inhibitioneffect of tested compounds or vaccines on Flavivirus by sandwich ELISAusing said monoclonal antibody.

The method for screening compounds against Flavivirus infection usingthe persistent virus-infected cell system of this invention comprises(a) establishment of persistent virus-infected cell lines, (b)preparation of monoclonal antibody by using said persistentvirus-infected cell lines, (c) incubation of tested compound with saidpersistent virus-infected cell lines, (d) determination of theinhibition effect of tested compounds or vaccines on Flavivirus bysandwich ELISA using said monoclonal antibody.

For the monoclonal antibody used in the screening of this invention, itis preferable to have epitopes of non-structural protein (NS1 protein)or envelop protein (E protein), and, more preferably, a cocktail ofthese two monoclonal antibodies.

Compounds selected by using the screening method of this invention canbe applied in the therapy and/or prophylaxis of Flavivirus infection.

Another embodiment of this invention is a kit for screening compoundsagainst Flavivirus infection comprising: (a) materials to establishpersistent virus-infected cell lines, (b) materials to preparemonoclonal antibody by using said persistent virus-infected cell lines,(c) guidelines for incubation of tested compound with said persistentvirus-infected cell lines, (d) materials to determine the inhibitioneffect of tested compounds or vaccines on Flavivirus by sandwich ELISAusing said monoclonal antibody. For the monoclonal antibody used in thisembodiment, it is preferable to use epitopes of non-structural protein(NS1 protein) or envelop protein (E protein), and, more preferably, acocktail of those two monoclonal antibodies.

Compounds selected by using the screening method of this invention canbe applied in the preparation of medication for therapy and/orprophylaxis of Flavivirus infection.

Flaviviruses suitable for the screening method of this inventioncomprise Genus Flavivirus of Flaviviridae, comprising: Tick-borneviruses (such as Russian spring-summer virus, Omsk hemorrhagic fevervirus, Powassan virus, Royal Farm virus, Karshi virus, Tick-borneencephalitis virus, Neudoerfl virus, Louping ill virus, Seabirdtick-borne virus and the like), Mosquito-borne viruses (such as Aroavirus, Bussuquara virus, Iguape virus, Dengue virus (type 1 to 4),Kedougou virus, Japanese encephalitis virus, Cacipacore virus, MurrayValley encephalitis virus, Alfuy virus, St. Louis encephalitis virus,Usutu virus, West Nile virus, Kunjin virus, Yaounde virus, Kokoberavirus, Stratford virus, Ntaya virus, Bagaza virus, Ilheus virus, Rociovirus, Israel turkey meningoencephalomyelitis virus, Tembusu virus,Spondweni virus, Zika virus, Yellow fever virus, Banzi virus, Boubouivirus, Edge Hill virus, Jugra virus, Saboya virus, Potiskum virus, Sepikvirus, Uganda S virus, Wesselsbron virus and the like), viruses with noknown arthropod vector(such as Entebbe virus, Entebbe bat virus, Sokolukvirus, Yokose virus, Modoc virus, Apoi virus, Cowbone Ridge virus,Jutiapa virus, San Perlita virus, Rio Bravo virus, Bukalasa bat virus,Carey Island virus, Dakar bat virus, Montana myotis leukoencephalitisvirus, Phnom Penh bat virus, Batu Cave virus and the like).

The methods to establish the Flavivirus persistent infected cell linescan use the methods described in the publications (Virology. 217:220, J.V. 71:5963, J. V. 72:9844) or any other known methods used to prepare apersistent virus infected cell line. K562 cells can be used as thepersistent virus-infected cells for the suspension cultivation, andBHK-21 cells, B2-5 cell line, and Bcl-2 expressing BHK-21 cells can beused for the attached cultivation. Cells will be infected withFlavivirus by incubation with virus. After most of the cytopathogeniceffect (CPE) on the cells disappears, the rest of the proliferatingcells will grow rapidly. The persistency of Flaviviruses infection isthen assayed with IFA and ELISA by using the Flavivirus-specificmonoclonal antibodies (described in this specification hereafter) as theprimary antibody, and the FITC-conjugated (fluoresceinisothiocyanate-conjugated) or HRP-conjugated (horseradishperoxidase-conjugated) goat-anti-mouse Ig antibody as the secondaryantibody.

In the screening method of this invention, epitope of monoclonalantibody can be any epitope of Flavivirus, comprising E protein, Cprotein, and structural and non-structural proteins, wherein preferablyit is composed of non-structural proteins. The monoclonal antibodiesused in this invention are prepared by using hybridoma techniquescomprising: (1) preparation of the conjugate of Flavivirus epitope and acarrier, wherein the conjugate is able to induce an immune reactionafter immunization using said conjugate and an animal body, followed bycollection of the antibody against Flavivirus epitope; (2) establishmentof analysis system (IFA and ELISA) for determining immune reaction andscreening animal sera or spleen cells having immune reaction; (3)Preparation and screening of hybridoma of animal spleen cells havingFlavivirus epitope and myeloma; and (4) Production of a large amountmonoclonal antibody by using said hybridoma.

Enzyme-linked immunosorbent assay (ELISA) used in the screening methodof this invention can be the direct or indirect enzyme-linkedimmunosorbent assay, preferably the sandwich enzyme-linked immunosorbentassay. The condition of sandwich ELISA for each monoclonal antibodyneeds to be optimized.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention can be more fully understood by reading thefollowing detailed description of the preferred embodiments, withreference made to the accompanying drawings, wherein:

FIG. 1 is a schematic diagram showing the design of a compound screeningsystem of this invention, wherein two parts are included in this system:establishment of a persistent virus-infected cell line and preparationof monoclonal antibody having epitope specificity with a hybridomatechnique, and after addition of the tested compound to the persistentvirus-infected cell, the supernatant of culture cell is subjected tosandwich ELISA for detection of viral antigen, and the culture cell canbe subjected to MTT assay for determination of cytotoxic effect(viability);

FIG. 2 is a schematic diagram showing the sandwich ELISA step of thisinvention, wherein in the sandwich ELISA step of this invention, primaryantibodies and secondary antibodies both can use a cocktail ofmonoclonal antibodies having epitope specificity; and

FIG. 3 is a schematic diagram showing the results of virus antigencontent secreted in the supernatant of persistent dengue virus-infected(type 2) cell cultures by sandwich ELISA, wherein the virus antigencontent in the supernatant of persistent virus-infected cell culturesestablished in this invention exhibits an increase of secreted viralantigen concentration.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Establishment of Persistent Flavivirus-infected Cell Line

The methods to establish the persistent Flavivirus-infecied cell lineshave been described in the publications (Virology. 217:220, J. V.71:5963, J. V. 72:9844). Cells of B2-5 line, Bcl-2 expressing BHK-21cells are infected with each type of Flavivirus (Table 1). After most ofthe cytopathogenic effect (CPE) on cells disappears, the rest of theproliferating cells will grow rapidly and the persistency ofFlaviviruses infection is then assayed with IFA and ELISA by using theFlavivirus-specific monoclonal antibodies (described in thisspecification hereafter) as the primary antibody and the FITC-conjugated(fluorescein isothiocyanate-conjugated) or HRP-conjugated (horseradishperoxidase-conjugated) goat-anti-mouse Ig antibody as the secondaryantibody.

Preparation of Flavivirus-specific Monoclonal Antibody by HybridomaTechnique

BALB/c mice were immunized with the supernatant of establishedpersistent Flaviviruses-infected cell lines to increase the chance ofgetting a monoclonal antibody against the secreted viral proteins inculture supernatants. The Flavivirus strains used are listed in Table 1.After immunization, IFA and ELISA were used to check the specificantibody titers of the sensitized sera before cell fusion. The specificantibody (B cell) is fused with myeloma. B cell cannot be culturedlong-term in a culture flask, and myeloma is a lymphoid tumor that canreplicate and proliferate in a culture flask without time limit. Thesetwo cells were mixed and induced to fuse with each other by PEG(polyethylene glycol). Recombination may occur after these two sets ofchromosomes are mixed, and then the chromosomes number might go back tonormal after several cycles of mitosis. The daughter cells, calledhybridoma, secrete the specific antibody and proliferate without limit.Once the target Flavivirus-specific monoclonal antibody produced byhybridoma was selected based on the characterization of monoclonalantibody, the production of antibody on large-scale can be accomplishedby induction of ascites in NOD/SCID mice because of the low rate ofcontamination by natural immunoglobulin from host mice. Purification ofthe specific monoclonal antibodies from ascites was carried out bypassing the ascites through the protein A or protein G column dependingon isotype information from typing ELISA. The characterization ofantigenic target molecules recognized by monoclonal antibodies can beconfirmed from the molecular weight of the colored band by the Westernblotting method. TABLE 1 Flaviviruses strain used for preparation ofmonoclonal antibodies Virus Strain Name Source Dengue Type 1 HAWAII ATCCDengue Type 2 PLO46 ATCC Dengue Type 3 H-87 ATCC Dengue Type 4 H-241ATCC West Nile VR-1510 ATCC JEV (Japanese RP9 Home Lab EncephalitisVirus) YFV (Yellow Fever Virus) 17D ATCCOptimization of Sandwich ELISA

The selection of monoclonal antibody to be used for sandwich ELISA wasbased on the ability of the monoclonal antibody to catch the viralprotein in the supernatants of persistent virus-infected cells. Thechoice of the pair of primary and secondary antibodies was done througha competitive test to make sure the epitopes recognized by these twoantibodies were different from each other. When there were more than oneviral proteins secreted into the cultural supernatants, the primaryantibody used for sandwich ELISA might be a cocktail of oligoclonalantibodies. The same principle was applied to choose the secondaryantibody for the sandwich ELISA.

The detailed procedures for sandwich ELISA are described as follows: acocktail of monoclonal antibodies against E and NS1 proteins offlavivirus used as primary antibody to capture secreted viral antigenswas coated on the wells of ELISA-microplate at 4° C. and allowed tostand overnight. After washing with PBS containing 1% BSA (3 times) forblocking, the culture supernatants from persistent infected cells wereadded to microwells and the microplates were incubated at 37° C. for 90minutes. After the microplates were washed with 1% BSA-containing PBS (3times), a cocktail of paired biotin-conjugated secondary antibody wasadded to each well and the microplates were incubated at 37° C. for 90minutes. The microplates were washed with PBS (3 times), thenhorseradish peroxidase-streptavidin was added to each well and themicroplates were incubated at room temperature for 30 minutes. Themicroplates were washed with PBS (3 times) and TMB substrate was addedto react for 30 minutes at room temperature. The results were readout atO. D. 405 nm with an ELISA-reader. Experiments on negative and positivecontrol groups were done by using culture supernatants from mock orFlavivoirus-infected cytopathic BHK-21 cells.

Consistent Screening of Viral Antigen in Supernatants of PersistentFlavivirus-infected Cell Lines

The viral antigens secreted into the supernatants of continuouslong-term (up to 6 months) cultured persistent Flavivirus-infected celllines could be directly detected by sandwich ELISA without anypre-treatments such as extraction or partial purification (FIG. 3).Furthermore, after 5 successive rounds of freezing for one week andcultivation for two weeks after thawing, the persistentFlavivirus-infected cell lines still secreted the same amount of viralantigens as at the beginning as detected by sandwich ELISA.

MTT assay

In the method of this invention, while the culture supernatants of celllines was subjected to sandwich ELISA, the cultured cells can beseparately subjected to MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)]assay to determine the cytotoxicity of the target compounds. MTT is asensitive reagent for the measurement based upon the high reductionproperty of tetrazolium salt. Changes in cell proliferation activitycaused by trophic factors, growth inhibitors, or inducers and inhibitorsof apoptosis, can be quantified by the MTT assay. MTT is reduced to aninsoluble formazan dye by mitochondria dehydrogenase enzymes associatedwidth metabolic activity. The reduction of MTT is primarily due toglycolytic activity within the cells and is dependent upon the presenceof NADH and NADPH. The formazan crystals must be dissolved withisopropanol and spectrophotometrically measured at 570 nm. The increasein MTF conversion is quantitatively proportional to the activelyproliferating cells. Experiments on negative and positive control groupswere conducted by using culture cells from mock or Flavivirus-infectedcytopathic BHK-21 cell.

Design of the Compound Screening System

This cell-based screening system for searching for antiviral drugs froma library of pharmaceutical compounds comprises two components. One is avirus infection component for testing the effects of candidate chemicalsadded into the culture of persistent Flavivirus-infected cells. Thesupernatant is monitored by virus-specific sandwich-ELISA. Cytotoxiceffects of the candidate chemicals are determined by checking viabilityof surviving cells by MTT assay. A simplified scheme of the design forthe compound screening system is shown in FIG. 1.

The screening system of this invention has the following advantages: useof isotope is not necessary, no follow-up treatment is required forisotope waste; the screening system of this invention is applicable to ageneral microplate auto machine in a lab, new equipment is not needed;the establishment of persistent virus-infected cell lines can avoidvirus instability and the repeated complicated operations for eachpreparation of virus infection; cytotoxic effect of compound can bedetermined by MTT assay at the same time as sandwich ELISA is performed;compounds selected from the screening method based on the use ofpersistent virus-infected cells will reveal the inhibition activity onthe intercellular viral protein expression, and modifications are notnecessary in order for compound to enter cells; viral-inhibition effectsof the compounds selected by epilope specific monoclonal antibody ishighly sensitive and not disturbed by other factors; a cocktail ofmonoclonal antibodies can be used in sandwich ELISA of this invention todetect various viral antigens simultaneously and to enhance theanti-viral accuracy of the selected compounds.

Interpretation of Screening Results

The interpretation of the results obtained by the method of thisinvention is straightforward. There is only one exceptional conditionwhich should be ruled-out before making a conclusion, which is there isthe possibility of interference involving antigen-antibody binding bythe target compounds. This condition could be easily avoided by reducingOD values due to the target compounds negative control group rightbefore sandwich ELISA determination.

The present invention has been described using exemplary preferredembodiments. However, it is to be understood that the scope of theinvention is not limited to the disclosed embodiments. On the contrary,it is intended to cover various modifications and similar arrangements.The scope of the claims, therefore, should be accorded the broadestinterpretation so as to encompass all such modifications and similararrangements.

1. A method for screening compounds against Flavivirus, comprising the steps of: (a) establishing persistent virus-infected cell lines; (b) preparing monoclonal antibody by using said persistent virus-infected cell lines; (c) incubating tested compounds with said persistent virus-infected cell lines; and (d) determining an inhibition effect of said tested compounds on said Flavivirus by sandwich ELISA using said monoclonal antibody.
 2. The method of claim 1, wherein said compounds are selected from natural compounds.
 3. The method of claim 1, wherein said compounds are selected from synthetic compounds.
 4. The method of claim 1, wherein said persistent virus-infected cell lines are established from suspension cell lines.
 5. The method of claim 4, wherein said suspension cell lines are K562 cell lines.
 6. The method of claim 1, wherein said persistent virus-infected cell lines are established from attached cell lines.
 7. The method of claim 6, wherein said attached cell lines are selected from BHK-21 cell lines, B2-5 cell lines, or Bcl-2 expressed BHK-21 cell lines.
 8. The method of claim 1, wherein said antibody used in said ELISA comprises one type of monoclonal antibody or a mixture of different types of monoclonal antibodies.
 9. The method of claim 1, wherein said monoclonal antibody is against epitope of said Flavivirus.
 10. The method of claim 9, wherein said monoclonal antibody is against non-structural (NS1) epitope of said Flavivirus.
 11. The method of claim 9, wherein said monoclonal antibody is against envelope protein (E protein) epitope of said Flavivirus.
 12. The method of claim 1, wherein said compounds are used as a therapy for and/or prophylaxis against Flavivirus infection.
 13. A medicament for a therapy for and/or prophylaxis against Flavivirus infection, which is prepared by using compounds selected by the method of claim
 1. 14. A screening kit for compounds against Flavivirus, comprising: (a) materials for establishment of persistent virus-infected cell lines; (b) materials for preparation of monoclonal antibody by using said persistent virus-infected cell lines; (c) materials for incubation of tested compounds with said persistent virus-infected cell lines; and (d) materials for determination of an inhibition effect of said tested compounds on said Flavivirus by sandwich ELISA using said monoclonal antibody.
 15. The screening kit of claim 14, wherein said compounds are selected from natural compounds.
 16. The screening kit of claim 14, wherein said compounds are selected from synthetic compounds.
 17. The screening kit of claim 14, wherein said persistent virus-infected cell lines are established from suspended cell lines.
 18. The screening kit of claim 17, wherein said suspended cell lines are K562 cell lines.
 19. The screening kit of claim 14, wherein said persistent virus-infected cell lines are established from attached cell lines.
 20. The screening kit of claim 19, wherein said attached cell line are selected from BHK-21 cell lines, B2-5 cell lines, or Bcl-2 expressed BHK-21 cell lines.
 21. The screening kit of claim 14, wherein said antibody used in said ELISA comprises one type of monoclonal antibody or a mixture of different types of monoclonal antibodies.
 22. The screening kit of claim 14, wherein said monoclonal antibody is against epitope of said Flavivirus.
 23. The screening kit of claim 22, wherein said monoclonal antibody is against non-structural (NS1) epitope of said Flavivirus.
 24. The screening kit of claim 22, wherein said monoclonal antibody is against envelope protein (E protein) epitope of said Flavivirus.
 25. The screening kit of claim 14, wherein said compounds are used as a therapy for and/or prophylaxis against Flavivirus infection. 